Solutions Through Immunology

Advancing Vaccines and BioTherapeutics

Our GMP, Your IND

Advancing Vaccines and BioTherapeutics

Breakthroughs Delivered

Advancing Vaccines and BioTherapeutics

About ABL

ABL, Inc. has been nominated for the Maryland Tech Council Life Science Company of the Year!

Learn More
Spotlight

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

Read More

ABL, Inc. Earned GCLP Certificate of Accreditation

In Q1 2017, ABL was awarded a certificate of full accreditation after satisfactorily implementing the requirements set out in the Good Clinical Laboratory Practice (GCLP), an international standard developed by the World Health Organization (WHO) to close the gap between preclinical GLP and GCP testing.

Learn More

ABL, Inc. Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID).

Read More

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL is pleased to announce the award of a contract for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention.” ABL will provide the Division of AIDS in the National Institute of Allergy and Infectious Disease with a comprehensive suite of preclinical product development services for candidate non-vaccine biomedical prevention products to prevent sexual HIV transmission.

Read More